Effect Of Adjuvant Therapy For Stage Ii And Iii Ovarian Cancer In Patients Older Than 70 Years.

e17557Background: Data on safety and efficacy of adjuvant chemotherapy for stage II and III ovarian cancer in elderly patients is not clearly defined as these patients are underrepresented in clinical trials. We did a retrospective analysis of elderly patients (≥70 years) with stage II and stage III ovarian cancer to investigate adjuvant chemotherapy effect on survival in these patients. Methods: Data was analyzed from 18, 890 women (≥ 70 years of age) registered in the National Cancer Database (NCDB) who were diagnosed with Stage II and Stage III ovarian cancer between 2004 and 2013 and had follow-ups to end of 2014. The primary predictor variable was adjuvant chemotherapy, and overall survival was the outcome variable. Additional variables addressed and adjusted included age, race, Charlson Comorbidity Index and grade of tumor. Results: The mean age was 67.6 years and SCD was 10.3 years. In multivariate analysis, after adjusting for secondary predictor variables, receipt of adjuvant chemotherapy for was...